IF=17.5! Phase I Data of Eratrectinib Published in Experimental Hematology & Oncology
Published Time:
2026-07-09 17:39
Source:
NTRK fusion gene is the first molecular biomarker approved for pan-tumor targeted therapy, earning it the reputation of a "diamond target". Larotrectinib, the first TRK inhibitor, obtained FDA approval in 2018 and obtained CFDA approval in 2022. Nevertheless, numerous unmet clinical needs persist among patients with NTRK fusion-positive solid tumors. On June 4, 2026, Eratrectinib, a next-generation TRK inhibitor independently developed in China, was granted marketing authorization. Recently, results from its Phase I clinical trial were published in Experimental Hematology & Oncology.
Literature Overview
Title: Safety, Efficacy and Pharmacokinetics of Eratrectinib (VC004) in NTRK Fusion-Positive Solid Tumors: Phase I Clinical Results from a Phase 1/2 Study
Journal: Experimental Hematology & Oncology
Publication Date: June 26, 2026
Impact Factor (IF): 17.5
Journal Ranking: Top Journal in Q1 of the Medicine Major Category in the 2026 New Release Journal Partition, JCR Q1
Key Study Outcome: Based on safety, pharmacokinetic (PK) and efficacy data, the Recommended Phase II Dose (RP2D) was finalized as 50 mg twice daily.
Professor Shi Yuankai, Principal Investigator of Eratrectinib (VC004) from Aerospace Center Hospital / National Cancer Center, Chinese Academy of Medical Sciences, stated: "The core tenet of precision medicine lies in delivering tangible clinical therapeutic value to patients with severe and refractory malignancies. The publication of our Phase I clinical findings in Experimental Hematology & Oncology lays a solid foundation for subsequent clinical research of Eratrectinib. We believe that as clinical investigations progress further, the efficacy and safety profile of Eratrectinib will be presented in a more comprehensive and objective manner."
Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech, commented: "As the first innovative drug developed by Vcare PharmaTech to receive marketing approval, Eratrectinib delivers pivotal clinical therapeutic benefits to patients with NTRK fusion-positive solid tumors. We are greatly encouraged that the Phase I clinical data of this agent has been formally published in Experimental Hematology & Oncology, an authoritative international journal covering hematology and oncology. This publication not only serves as high recognition of the high quality and rigorous design of our clinical trial, but also further demonstrates our robust R&D capabilities."
At present, Eratrectinib has successfully completed pivotal Phase II clinical trials and obtained marketing approval. Its Phase III clinical trial enrolling a broader patient population is actively recruiting participants. Phase II data demonstrated that patients with more than 6 months of follow-up achieved an Objective Response Rate (ORR) of 89.7% and a median Overall Survival (mOS) of 40.7 months, with a treatment discontinuation rate of only 2.2% due to Adverse Drug Reactions (ADRs), reflecting outstanding efficacy and favorable safety.
With continuous advancement of follow-up clinical studies and accumulation of real-world evidence, the long-term efficacy and safety of Eratrectinib will be more fully validated, and its indication scope is expected to expand further. This will provide more robust treatment options and new clinical alternatives for domestic patients diagnosed with NTRK fusion-positive solid tumors.
Previous Page
Related News
15
2017
/
06
Jiangsu Vcare and Yangzhou Princechem Acquired Boya Chemical Company
The signing ceremony of Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and Yangzhou Princechem Co., Ltd. acquiring Boya Chemical (Nantong) Co., Ltd. was held in the conference room of Jiangsu Vcare recently. Boya Chemical (Nantong) Co., Ltd. is located in Yangkou Chemical Industrial Park, Rudong Coastal Economic Development Zone, Jiangsu Province. The company covers an area of 70 acres and is a Hong Kong-owned enterprise. The goal of this acquisition is to build Boya Chemical into a raw material drug manufacturer that meets the standards of China, the United States and the European Union. After renovation, Boya Chemical will be a chemical raw materials production base of Yatai Group and solve the bottleneck problem of Vcare's raw material drug R&D and production. It’s believed that the acquisition will make a significant contribution to Vcare’s production and sales of intermediates and APIs.
View Details
06
2017
/
06
Leaders of Management Committee of Rudong Coastal Economic Development Zone Visited Jiangsu Vcare
Leaders of management committee of Rudong coastal economic development zone visited Jiangsu Vcare on June 1st, 2017. The delegation was received by the vice chairman Jun Qu, general manager Yongqiang Liu, and vice general manager Yanchun Gong of Vcare. The delegation visited the Vcare's chemical research center and drug research center. Mr. Liu introduced R&D progress and advanced equipment to the guests. During the discussion, Mr. Liu introduced the overall development plan of Yatai Group's pharmaceutical industry, and Vcare's development history and the future plan. Mr. Liu also introduced the progress of innovative drug Vicagrel and a series of generic drugs in detail. The leaders of Rudong coastal economic development zone introduced the planning of their park, local investment, environmental protection policies and etc., and expressed their confidence in the research and development prospects of Vcare.
View Details
15
2017
/
05
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare
Leaders of Pukou District Economic and Trade Bureau Visited Jiangsu Vcare on May 12, 2017. The general manager Yongqiang Liu received the delegation.
View Details
24
2017
/
04
Jiangsu Vcare Held Mountain Climbing and Tug-of-war Competitions
Jiangsu Vcare organized mountain climbing and tug-of-war activities recently. The mountain climbing competition was divided into men's and women's groups, and each group competed for top three. The venue was located in Laoshan National Forest Park. Everyone climbed the top after efforts. Four teams consisting of Vcare’s two R&D center members conducted a tug-of-war competition after going down the mountain and finally "Lingya team" won the top spot. Everyone had fun.
View Details
30
2017
/
03
Jiangsu Vcare Held the First Quarter Fire Drill
In order to further improve the safety awareness of new employees, Jiangsu Vcare held a fire-fighting exercise on March 30, 2017. New employees had a deeper understanding of fire extinguishers through on-site explanation of the types, inspection methods and instructions of fire extinguishers. Everyone learned about fire-fighting procedures and the use of appliances. The exercise provided a safety guarantee for everyone’s life and work.
View Details
27
2017
/
03
Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare
The delegation of Political Consultative Conference of Wenzhou Ouhai District, accompanied by vice chairman of Political Consultative Conference of Pukou Economic Development Zone visited Jiangsu Vcare Pharmaceutical Technology Co., Ltd. on the afternoon of March 27, 2017. Yongqiang Liu, the general manager of Jiangsu Vcare received the delegation. Mr. Liu introduced the company's development history and R&D progress. He focused on the progress of phase II clinical trials and the future market prospect of innovative drug Vicagrel. The delegation highly recognized Vcare's advanced equipment and facilities, harmonious human environment and comprehensive research and development capabilities.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn